[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-malignant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-malignant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641744","phase-1-a-study-of-sim0689-in-adult-participants-with-locally-advanced-or-metastatic-solid-tumors-100641744",false,"NCT07660432","A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","Phase I First-in-Human, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* In dose-escalation cohorts (Part 1), histologically or cytologically documented advanced or metastatic solid tumor that is refractory\u002Frelapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.\n* In the dose-expansion cohorts (Part 2), histologically or cytologically confirmed selected advanced solid tumors.\n* Subjects must have at least one measurable lesion according to RECIST Version1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.\n* Adequate organ function.\n* Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.\n* Life expectancy ≥12 weeks.\n* Patients of childbearing potential (male and female) must agree to use reliable methods of contraception until at least 180 days after the last dose.\n\nExclusion Criteria:\n\n* Symptomatic brain metastases.\n* Serious non-healing wounds, ulcers or fractures.\n* Toxicity from previous treatment has to restore to ≤ grade 1.\n* Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to enrollment.\n* Use of aspirin (\\> 325 mg\u002Fday) within 6 months prior to the first dose.\n* Active hepatitis B or hepatitis C.\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).\n* Known hereditary or acquired predisposition to bleeding and thrombosis.\n* History of gastrointestinal perforation, gastrointestinal bleeding, fistula, or any life-threatening bleeding event within 6 months prior to enrollment.\n* Prior permanent discontinuation of PD-(L)1 and\u002For VEGF monoclonal antibody because of immune\u002Fanti-angiogenesis toxicities, or history of Grade ≥3 immune\u002Fanti-angiogenesis-related AEs\n* Known or suspected active autoimmune disease.\n* Patients with proteinuria at screening (Urine protein \\>2+ at screening, or 2+ urine protein accompanied by 24-h urine protein ≥1 g\u002F24 h).\n* History of myocardial infarction or stroke within 6 months prior to enrollment.\n* Subjects with clinically significant cardiovascular disease within 6 months prior to the first dose.\n* Pregnant and lactating women.\n* Known allergies to any excipient in the study drug.","ALL","18 Years",{"count":19,"type":20},472,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study will evaluate the safety, of SIM0689 and how the body processes it, how it affects the body, and its early signs of activity against tumors when given alone to Adult Participants with Locally Advanced or Metastatic Solid Tumors. The study has a dose escalation part to find the highest dose that can be given safely, or recommended dose (RD) for SIM0689 when given alone, and a dose expansion part in subjects with specific tumor types treated with SIM0689 as a single agent at RD.",[26],"Neoplasms, Malignant","NOT_YET_RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-22","ACTUAL",{"date":33,"type":20},"2027-07",{"date":35,"type":20},"2029-06",{"name":37,"class":38},"Jiangsu Simcere Pharmaceutical Co., Ltd.","INDUSTRY",6,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100511457","phase-3-prophylactic-mesh-placement-during-stoma-closure-after-low-anterior-resection-100511457","NCT05939687","Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection","Prophylactic Mesh Placement During Temporary Stoma Closure: a Prospective Randomized Phase III Clinical Trial","ProMeLAR","Inclusion Criteria:\n\n* Signed informed consent\n* Absence of distant metastases (M0)\n* ECOG (Eastern Cooperative Oncology Group) status 0-2\n* completed course of adjuvant treatment\n* Absence of acute inflammatory parastomal complications\n* Integrity of colorectal anastomosis\n\nExclusion Criteria:\n\n* Inability to obtain consent to participate\n* Synchronous and metachronous malignant neoplasms\n* Clinically significant diseases of the cardiovascular system, liver, kidney, central nervous system\n* Parastomal inflammation and other conditions that increase the risk of postoperative complications\n* Pregnancy\n* HIV infection","85 Years",{"count":50,"type":20},142,[52],"PHASE3","The goal of this clinical trial is to compare the efficacy of using polypropylene mesh for hernia prevention after stoma closure in patients with colorectal cancer and non-mesh repair. The main question it aims to answer is: can mesh help prevent hernia? Participants will be divided into 2 groups: with and without mesh using. They must be followed up for 2 years after enrollment in the study.\n\nResearchers will compare mesh and non-mesh groups to evaluate the benefits and harms of mesh using in hernia prevention.",[55,56,57,58],"Neoplasms Malignant","Rectal Cancer","Hernia Incisional","Surgery",[60,61,62,63,64],"Rectal cancer","mesh","stoma-site hernia","prevention","surgery","RECRUITING","2024-08-06",{"date":68,"type":31},"2024-08-07",{"date":70,"type":31},"2023-06-05",{"date":72,"type":20},"2028-12-01",{"name":74,"class":75},"Blokhin's Russian Cancer Research Center","OTHER",1]